Aromatase inhibitors versus antioestrogens

Breast Cancer Research

Volumn 6, Issue 6, 2004, Pages 269-274

  Howell, Anthony ^a   Dowsett, Mitch ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Breast cancer; Endocrine therapy; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADVANCED CANCER; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; HUMAN; NONHUMAN; POSTOPERATIVE CARE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; ENZYMOLOGY; FEMALE; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN;

EID: 7444220019     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr945     Document Type: Review

References (40)

1. Smith IE, Harris AL, Morgan M: Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 1982, Suppl:3430s-3433s.
2. Gale KE, Anderson JW, Tormey DC: Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer 1994, 12: 630-1638.
3. Perez Carrion R, Alberola Candel V, Calabresi F: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994, Suppl 7:19-24.
4. Thurlimann B, Beretta K, Bacchi M: First-line fadrozole HCl (CGS-16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996, 7: 71-479.
5. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomised, cross-over study. J Clin Oncol 2002, 20: 51-757.
6. Gershanovich M, Chaudri HA,Campos D: Randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Control Group (AR/BC3). Ann Oncol 1998, 9:639-645.
7. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, et al.: An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003, 39: 2318-2327.
8. Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI 146474. Br J Cancer 1971, 25:270-275.
9. Mouridson H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleebom HP, Joenicke F, et al.: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 2003, 21:2101-2109.
10. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, et al.: Mature results of a randomised phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003, 14:1391-1398.
11. Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, Casanovas J, Puig-Gali M: Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer. Am J Clin Oncol 2003, 26: 317-322.
12. Nabholtz JM, Buzdar A, Pollak M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18: 758-3776.
13. Eierman W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomised double-blind multicenter study. Ann Oncol 2001, 132:1527-1532.
14. Baum M,Cuzick J, Forbes J, Houghton J,Howell A (The ATAC Trialists Group): Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98:1802-1810.
15. Boccardo F, Rubagooi J, Amoroso D, Mesiti M, Masoobrio M, Porpiglia M, Rinaldini M, Paladini G, Distante V, Franchi R, et al. Anastrozole appears to be superior to tamoxifen in women already receiving tamoxifen treatment [abstract]. Breast Cancer Res Treat 2003, Suppl 1:S6.
16. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
17. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Mansi J, Castiglioni M, Dongsheng T, Shepherd L, et al.: A randomized double-blind clinical trial evaluating Letrozole adjuvant therapy in postmenopausal women with early stage breast cancer completing five years of tamoxifen. N Engl J Med 2003, 349:1793-1802.
18. Ellis MJ, Coop A, Singh B, Mauriac L, Llambert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19:3808-3816.
19. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, vonEuler M: Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 2000, 18:3748-3757.
20. Dixon JM, Love CDB, Renshaw L, Bellamy C, Cameron DA, Miller WR, Leonard RCF: Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 1999, 6:227-230.
21. Long BJ, Jelovac D, Thiantnawat A, Brodie AM: Effect of second line antiestrogen therapy on breast tumour growth following first line treatment with the aromatase inhibitor letrozole: long term studies using the intratumoural aromatase model. Clin Cancer Res 2002, 8:2738-2388.
22. Long BJ, Jelovac D, Pherson N, Ragaz J, Goloubeva G, Brodie A: Therapeutic atrategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 2004, 96:465-465.
23. Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signalling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003, 9: 47S-454S.
24. Nemere I, Pietras RJ, Blackmore PF: Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem 2003, 88:436-445.
25. Kurokawa H, Arteaga CL: ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003, 9:511S-515S.
26. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003, 95:353-361.
27. Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bieche I: Expression analysis of estrogen receptor coregulators in breast carcinoma: evidence that NCOR1 expression is predictive for the response to tamoxifen. Clin Cancer Res 2003, 9:1259-1266.
28. Howell A, Dodwell D, Anderson H, Redford J: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992, 3:611-617.
29. Osborne KO, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of breast cancer. J Natl Cancer Inst 1995, 87: 46-750.
30. Gottardis MM, Jiang MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989, 49: 090-4093.
31. DeFriend D, Anderson E, Bell J, Wilks DP, West CML, Howell A: Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro Br J Cancer 1995, 70:204-221.
32. Ellis M J, Coop A, Singh B, Tao Y, Liombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, et al.: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003, 63: 523-6231.
33. Masamura S, Santner SJ, Heitjan DF, Santen RJ: Estrogen deprivation causes estrogen hypersensitivity in human breast cancer cells J Clin Endocrinol Metab 1995, 80:2918-2925.
34. Martin LA, Farmer I, Johnston SRD, Ali S, Marshall C, Dowsett M: Enhanced estrogen receptor (ER)α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003, 278: 0458-30468.
35. Bernstein LM, Zheng H, Yue W, Wang J-P, Lykkes feldt AE, Naftolin F, Harada N, Shanabrough M, Santen RJ: New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer 2003, 10:267-277.
36. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng M-H, Masamura S, Yue W, Berstein L: Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 2003, 10:111-130.
37. Allred DC, Harvey JM, Berardo M: Prognosis and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.
38. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, et al.: Quantitative association between HER/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003, 95:142-153.
39. Dowsett M, on behalf of the ATAC Trialists Group: Analysisof time to recurrence in the ATAC trial according to estrogen receptor and progesterone receptor status [abstract]. Breast Cancer Res Treat 2003, Suppl 1:S27.
40. Ellis M: Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 2004, Suppl 3:20-26.